Mosaic ImmunoEngineering, Inc. (CPMV)

OTCMKTS: CPMV · Delayed Price · USD
1.20
0.00 (0.42%)
May 18, 2022 4:00 PM - Market closed
Market Cap8.69M
Revenue (ttm)n/a
Net Income (ttm)-763.49B
Shares Out7.24M
EPS (ttm)-0.55
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume125
Open1.20
Previous Close1.20
Day's Range1.20 - 1.20
52-Week Range0.10 - 3.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About CPMV

Mosaic ImmunoEngineering Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. It offers MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in mice, dogs, and humans. The company was founded in 2020 and is based in Novato, California.

IndustryBiotechnology
Founded1992
CEOCarlton Johnson
Employees3
Stock ExchangeOTCMKTS
Ticker SymbolCPMV
Full Company Profile

News

Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve Uni...

The licensed technology was jointly invented by researchers at Case Western Reserve University and Dartmouth College The license covers the use of plant viruses such as cowpea mosaic virus (CPMV) for th...

1 week ago - Accesswire

Newly Published Data Further Support Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 in Combination...

Broad, durable, and systemic anti-tumor immunity observed using inCPMV with OX40 agonist antibodies Intratumoral inCPMV administration in combination with systemic anti-OX40 controlled the progression o...

3 months ago - Accesswire

Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation

- Nanoparticle technology shown to be effective in transforming immunologically "cold" tumors to "hot" - - Data presented support durable antitumor activity - NOVATO, CA / ACCESSWIRE / November 1, 2021 ...

6 months ago - Accesswire

Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference

Presentation to highlight Mosaic's naturally-derived immuno-oncology candidate, MIE-101 Intratumoral administration of MIE-101 activates immune cells to initiate potent, systemic and durable antitumor i...

6 months ago - Accesswire

Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering's Immuno-Oncology ...

Presentation detailed the Company's COVID-19 vaccine candidates that generated antibodies that neutralized SARS-CoV-2 infection of human cells Vaccine candidates hold potential for rapid response to reg...

7 months ago - Accesswire

Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the Univers...

- Nanoparticle-based technology complements the company's intratumoral technology platform - NOVATO, CA / ACCESSWIRE / October 6, 2021 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTCQ...

7 months ago - Accesswire

Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering's Lead Immuno-Onc...

NOVATO, CA / ACCESSWIRE / October 1, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and engineer...

7 months ago - Accesswire

Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology

- Presentation highlighted potential of polymer-based delivery system for slow-release of vaccines that potentially require no booster shots - - Delivery system is transportation and storage friendly wi...

7 months ago - Accesswire

Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates ...

Vaccine candidates triggered high production of neutralizing antibodies against SARS-CoV-2 and SARS-CoV-1 in preclinical studies Epitopes used in the vaccine candidates are located in regions that are n...

7 months ago - Accesswire

Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with t...

- Licensed Candidates Hold Potential to Address Emerging SARS-CoV-2 and other Infectious Diseases Including Human and Veterinary Applications - - Data Supporting the Potential of Lead Vaccine Candidates...

7 months ago - Accesswire

Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering's Lead Intratumoral Im...

- Results Demonstrate Innate Immune System Activation Through Stimulation of Three Toll-Like Receptors (TLRs 2,4,7) - - MIE-101 Therapy Reduced Tumor Growth by 80% Compared to Tumors Treated with Agents...

10 months ago - Accesswire

Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting

NOVATO, CA / ACCESSWIRE / June 28, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused onimmunotherapies to treat and preven...

10 months ago - Accesswire

Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D.

Experience in the Development of Biotechnology and Viral Based Therapeutics Will Help Enhance the Development of the Company's Pipeline NOVATO, CA / ACCESSWIRE / June 15, 2021 / Mosaic ImmunoEngineering...

11 months ago - Accesswire